- Maxacalcitol therapy decreases circulating osteoprotegerin levels in dialysis patients with secondary hyperparathyroidism. Kazama, J.J., Omori, K., Takahashi, N., Ito, Y., Maruyama, H., Narita, I., Gejyo, F., Iwasaki, Y., Fukagawa, M. Clin. Nephrol. (2005)